Nanoactive Technology

  • Conversion of Sirolimus drug into sub-micron sized particles
  • Nanocarriers created by encapsulation of sub-micron sized Sirolimus drug into highly biocompatible drug Carrier-phospholipid
  • Encapsulated Sirolimus is coated on stent and parts of balloon
  • Upon implantation of Abluminus NP at target site, Nanocarriers with Sirolimus drug from stent and parts of balloon get transferred to the vessel wall following the principle of co-efficient diffusion
  • Upon body pH variation, Nanocarriers mimics the body lipids and liberates Sirolimus
  • The sub-micron sized Sirolimus drug particles penetrate the deepest layer of the vessel over a period

Advantages of Nanoactive Technology

  • Better in-tissue bioavailability of drug

  • Effective drug transfer to the deepest layer of the vessel

  • Reduces drug dose

  • Protect drug by encapsulation- reduced in-transit drug loss

Healing
Delayed
Acute/Sub
Acute/Late Stent
Thrombosis
Re-Stenosis
Focal/Edge
DAPT Related
Issues
  • ABLUMINAL COATING

    Drug is coated on the abluminal side only.
    Leading to mono directional drug release & less systemic exposure of drug which leads to faster healing

  • FUSION COATING

    Drug is coated on stent as well as exposed parts of balloon & coated on the proximal and distal ends.
    Helps to address the entire disease area of lesion and address focal restenosis and edge restenosis.

  • POLYMER FREE NANO CARRIER DRUG DELIVERY

    Designed for acute as well as sustained drug transfer in arterial wall – leading to less chronic inflammation and improved vascular healing.

  • POLYMER FREE COATING

    Proposed the shorter DAPT which helps to reduced bleeding risk in patients with high bleeding risk

Release mechanism of Sirolimus by NANOACTIVE

The release chart clearly indicated that sirolimus was delivered from the stents with an initial burst followed by a sustained release for up to 40 days.

Product Designed using NANOACTIVE TECHNOLOGY